Myriad Genetics, Inc.
MYGN
$6.61
-$0.18-2.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.76% | -3.12% | 7.12% | 11.15% | 15.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.76% | -3.12% | 7.12% | 11.15% | 15.26% |
| Cost of Revenue | -4.81% | -4.49% | -3.08% | 10.24% | 11.42% |
| Gross Profit | 3.20% | -2.47% | 11.78% | 11.54% | 17.02% |
| SG&A Expenses | -4.28% | -3.49% | -1.95% | 2.20% | 2.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.57% | -2.26% | 2.98% | 6.16% | 7.60% |
| Operating Income | 49.80% | -3.94% | 29.96% | 31.01% | 31.22% |
| Income Before Tax | -788.71% | -13.51% | -21.05% | 65.36% | 67.96% |
| Income Tax Expenses | 80.00% | -29,400.00% | 409.09% | 800.00% | -- |
| Earnings from Continuing Operations | -800.54% | 99.62% | -36.22% | 63.95% | 68.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -800.54% | 99.62% | -36.22% | 63.95% | 68.39% |
| EBIT | 49.80% | -3.94% | 29.96% | 31.01% | 31.22% |
| EBITDA | 116.33% | -19.67% | 73.96% | 87.36% | 57.21% |
| EPS Basic | -782.00% | 99.62% | -28.73% | 67.52% | 71.49% |
| Normalized Basic EPS | 46.83% | -11.60% | 43.65% | 36.39% | 40.20% |
| EPS Diluted | -782.00% | 99.62% | -27.80% | 67.59% | 71.49% |
| Normalized Diluted EPS | 46.83% | -11.60% | 43.65% | 36.39% | 40.20% |
| Average Basic Shares Outstanding | 2.10% | 1.67% | 5.81% | 10.99% | 10.89% |
| Average Diluted Shares Outstanding | 2.10% | 1.67% | 5.81% | 10.99% | 10.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |